Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
Evaxion Biotech A/S (NASDAQ: EVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
Evaxion announces business update and third quarter 2024 financial results
Evaxion to announce business update and third quarter 2024 financial results on October 31